Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 143.4% in April

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 19,602 shares, a growth of 143.4% from the March 31st total of 8,053 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 26,450 shares, the short-interest ratio is presently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors own 11.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix has a consensus rating of “Sell”.

Pulmatrix Trading Down 1.5%

Shares of PULM opened at $1.33 on Tuesday. Pulmatrix has a 12-month low of $1.16 and a 12-month high of $9.37. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $3.02. The firm has a market capitalization of $4.85 million, a P/E ratio of -0.94 and a beta of 1.97.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).